Alzheimer's in Focus as FDA Panel Endorses Lilly's Donanemab (Revised)
Biogen Inc. Common Stock · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · Now $192.23
+2.3% in 7d after detection
Post-detection moves
1h
—
1d
-0.7%
3d
-1.3%
7d
+2.3%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS